Cargando…

Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT

SIMPLE SUMMARY: Small intestinal neuroendocrine tumors (SI-NETs) are slow growing tumors expressing somatostatin receptors (SSTR), which are targeted in diagnostic and therapeutic methods. A fairly new treatment that targets SSTR2 is peptide receptor radionuclide therapy (PRRT), which prolongs survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elf, Anna-Karin, Johanson, Viktor, Marin, Ida, Bergström, Anders, Nilsson, Ola, Svensson, Johanna, Wängberg, Bo, Bernhardt, Peter, Elias, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122794/ https://www.ncbi.nlm.nih.gov/pubmed/33922482 http://dx.doi.org/10.3390/cancers13092035

Ejemplares similares

Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial
por: Elf, Anna-Karin, et al.
Publicado: (2017)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Abstracts of Poster Presentations (NET/ PRRT/ Molecular Imaging/ Radiopharmacy)
Publicado: (2011)

mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer
por: Shahbaz, Muhammad, et al.
Publicado: (2015)

The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer
por: Zanjani, Farhad Safari, et al.
Publicado: (2019)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [(177)Lu]Lu-DOTATATE Treatment
por: Hemmingsson, Jens, et al.
Publicado: (2023)

Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume
por: Svensson, Johanna, et al.
Publicado: (2016)

Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis
por: War, Sajad A, et al.
Publicado: (2012)

Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
por: Dalm, Simone U., et al.
Publicado: (2017)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [(111)In]In-DOTATATE Uptake in NET Cells
por: Klomp, Maria J., et al.
Publicado: (2021)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity
por: Svensson, Johanna, et al.
Publicado: (2016)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Renal function affects absorbed dose to the kidneys and haematological toxicity during (177)Lu-DOTATATE treatment
por: Svensson, Johanna, et al.
Publicado: (2015)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
por: Larsson, Maria, et al.
Publicado: (2012)

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020)

Molecular simulations of SSTR2 dynamics and interaction with ligands
por: Gervasoni, Silvia, et al.
Publicado: (2023)

Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Yu, Benxia, et al.
Publicado: (2017)

Retracted: Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Song, Hao, et al.
Publicado: (2018)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

PRRT2, a network stability gene
por: Michetti, Caterina, et al.
Publicado: (2017)

New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022)

Childhood Adversities are not a Predictors of SSTR4met in Alcoholics
por: Berent, Dominika, et al.
Publicado: (2017)

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
por: Mizutani, Gou, et al.
Publicado: (2012)

Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin
por: Johanson, V, et al.
Publicado: (1999)

PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
por: Li, Ming, et al.
Publicado: (2015)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Paroxysmal Dyskinesias in a PRRT2 Mutation Carrier
por: Marano, Massimo, et al.
Publicado: (2018)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n2tkenq48gsoutnijosd0nakaf